30 Participants Needed

ADCT-901 for Solid Tumors

Recruiting at 12 trial locations
CA
Overseen ByContact ADC Therapeutics
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: ADC Therapeutics S.A.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objectives of this study are to identify the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.

Are You a Good Fit for This Trial?

This trial is for adults with certain advanced solid tumors (like cholangiocarcinoma, ovarian, prostate cancer, renal cell carcinoma, and TNBC) that are measurable and have not responded to or can't tolerate current treatments. Participants should not have active severe diarrhea or eye diseases, recent serious infections requiring IV treatment, symptomatic brain metastases or leptomeningeal disease.

Inclusion Criteria

My current treatment isn't working or causes severe side effects.
My cancer has spread to my bones, but it can be measured by scans.
I have prostate cancer with bone metastases and a PSA level of 2.0 ng/mL or higher.
See 3 more

Exclusion Criteria

I have severe or chronic diarrhea.
I have mild eye conditions but not an active eye disease.
I do not have any significant eye diseases or history of severe conjunctivitis.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive escalating doses of ADCT-901 as monotherapy until disease progression, adverse event, or other discontinuation criteria

Variable

Dose Expansion

Participants receive ADCT-901 monotherapy at the dose identified as the RP2D/MTD in Part 1 until disease progression, adverse event, or other discontinuation criteria

Variable

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to approximately 2.5 years

What Are the Treatments Tested in This Trial?

Interventions

  • ADCT-901
Trial Overview The study tests ADCT-901's safety and tolerability to find the right dose for phase 2 trials. It aims to see how participants' bodies handle the drug (pharmacokinetics) and its effectiveness against selected solid tumors at different doses.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Part 2: Dose ExpansionExperimental Treatment1 Intervention
Group II: Part 1: Dose EscalationExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

ADC Therapeutics S.A.

Lead Sponsor

Trials
32
Recruited
2,700+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security